+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07706777

Evaluating Safety and Effectiveness of HRS-2129 Tablets Compared to Placebo in Adults with Acute Gouty Arthritis

Led by Shandong Suncadia Medicine Co., Ltd. · Updated on 2026-09-03

90

Participants Needed

2

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a drug called HRS-2129 in people with acute gouty arthritis. The study also aims to determine the appropriate dosage of HRS-2129 for treating this condition. This is a phase 2 clinical trial that compares different doses of the drug to a placebo. Participants will be randomly assigned to one of three groups a high dose of HRS-2129 tablet, a low dose of HRS-2129 tablet, or a placebo tablet. The treatment is given as tablets, and the study uses a quadruple masking design so that participants and researchers do not know which group each participant is in. The study period includes monitoring responses at multiple time points after the first dose, lasting up to 15 days. During the study, participants will have their pain levels measured frequently using a Visual Analog Scale VAS at various hours after dosing, including 1, 2, 6, 12, 18, 24, 48, and 72 hours. Researchers will also track the time until pain fully disappears in the affected joint and monitor daily pain changes and any adverse events for safety up to 14 days after the last dose. The total participation spans from consent signing through these follow-up assessments.

CONDITIONS

Brief Title

Clinical Study of HRS-2129 for Acute Gouty Arthritis

Research Team

L

Lei Tang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here